<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1997-11-01" modified="2020-10-07" version="199">
<accession>Q12948</accession>
<accession>Q86UP7</accession>
<accession>Q9BYM1</accession>
<accession>Q9NUE5</accession>
<accession>Q9UDD0</accession>
<accession>Q9UP06</accession>
<name>FOXC1_HUMAN</name>
<protein>
<recommendedName>
<fullName>Forkhead box protein C1</fullName>
</recommendedName>
<alternativeName>
<fullName>Forkhead-related protein FKHL7</fullName>
</alternativeName>
<alternativeName>
<fullName>Forkhead-related transcription factor 3</fullName>
<shortName>FREAC-3</shortName>
</alternativeName>
</protein>
<gene>
<name type="primary">FOXC1</name>
<name type="synonym">FKHL7</name>
<name type="synonym">FREAC3</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1998" name="Nat. Genet." volume="19" first="140" last="147">
<title>The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25.</title>
<authorList>
<person name="Nishimura D.Y."/>
<person name="Swiderski R.E."/>
<person name="Alward W.L.M."/>
<person name="Searby C.C."/>
<person name="Patil S.R."/>
<person name="Bennet S.R."/>
<person name="Kanis A.B."/>
<person name="Gastier J.M."/>
<person name="Stone E.M."/>
<person name="Sheffield V.C."/>
</authorList>
<dbReference type="PubMed" id="9620769"/>
<dbReference type="DOI" id="10.1038/493"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS ASGD3 SER-112; MET-126 AND LEU-131</scope>
<scope>INVOLVEMENT IN ASGD3</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1998" name="Am. J. Hum. Genet." volume="63" first="1316" last="1328">
<title>Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly.</title>
<authorList>
<person name="Mears A.J."/>
<person name="Jordan T."/>
<person name="Mirzayans F."/>
<person name="Dubois S."/>
<person name="Kume T."/>
<person name="Parlee M."/>
<person name="Ritch R."/>
<person name="Koop B."/>
<person name="Kuo W.-L."/>
<person name="Collins C."/>
<person name="Marshall J."/>
<person name="Gould D.B."/>
<person name="Pearce W."/>
<person name="Carlsson P."/>
<person name="Enerbaeck S."/>
<person name="Morissette J."/>
<person name="Bhattacharya S."/>
<person name="Hogan B."/>
<person name="Raymond V."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="9792859"/>
<dbReference type="DOI" id="10.1086/302109"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS RIEG3 THR-82 AND MET-87</scope>
<scope>INVOLVEMENT IN RIEG3</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2003" name="Mol. Vis." volume="9" first="43" last="48">
<title>Mutation spectrum of FOXC1 and clinical genetic heterogeneity of Axenfeld-Rieger anomaly in India.</title>
<authorList>
<person name="Komatireddy S."/>
<person name="Chakrabarti S."/>
<person name="Mandal A.K."/>
<person name="Reddy A.B.M."/>
<person name="Sampath S."/>
<person name="Panicker S.G."/>
<person name="Balasubramanian D."/>
</authorList>
<dbReference type="PubMed" id="12592227"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANT RIEG3 LYS-161</scope>
</reference>
<reference key="4">
<citation type="journal article" date="2003" name="Nature" volume="425" first="805" last="811">
<title>The DNA sequence and analysis of human chromosome 6.</title>
<authorList>
<person name="Mungall A.J."/>
<person name="Palmer S.A."/>
<person name="Sims S.K."/>
<person name="Edwards C.A."/>
<person name="Ashurst J.L."/>
<person name="Wilming L."/>
<person name="Jones M.C."/>
<person name="Horton R."/>
<person name="Hunt S.E."/>
<person name="Scott C.E."/>
<person name="Gilbert J.G.R."/>
<person name="Clamp M.E."/>
<person name="Bethel G."/>
<person name="Milne S."/>
<person name="Ainscough R."/>
<person name="Almeida J.P."/>
<person name="Ambrose K.D."/>
<person name="Andrews T.D."/>
<person name="Ashwell R.I.S."/>
<person name="Babbage A.K."/>
<person name="Bagguley C.L."/>
<person name="Bailey J."/>
<person name="Banerjee R."/>
<person name="Barker D.J."/>
<person name="Barlow K.F."/>
<person name="Bates K."/>
<person name="Beare D.M."/>
<person name="Beasley H."/>
<person name="Beasley O."/>
<person name="Bird C.P."/>
<person name="Blakey S.E."/>
<person name="Bray-Allen S."/>
<person name="Brook J."/>
<person name="Brown A.J."/>
<person name="Brown J.Y."/>
<person name="Burford D.C."/>
<person name="Burrill W."/>
<person name="Burton J."/>
<person name="Carder C."/>
<person name="Carter N.P."/>
<person name="Chapman J.C."/>
<person name="Clark S.Y."/>
<person name="Clark G."/>
<person name="Clee C.M."/>
<person name="Clegg S."/>
<person name="Cobley V."/>
<person name="Collier R.E."/>
<person name="Collins J.E."/>
<person name="Colman L.K."/>
<person name="Corby N.R."/>
<person name="Coville G.J."/>
<person name="Culley K.M."/>
<person name="Dhami P."/>
<person name="Davies J."/>
<person name="Dunn M."/>
<person name="Earthrowl M.E."/>
<person name="Ellington A.E."/>
<person name="Evans K.A."/>
<person name="Faulkner L."/>
<person name="Francis M.D."/>
<person name="Frankish A."/>
<person name="Frankland J."/>
<person name="French L."/>
<person name="Garner P."/>
<person name="Garnett J."/>
<person name="Ghori M.J."/>
<person name="Gilby L.M."/>
<person name="Gillson C.J."/>
<person name="Glithero R.J."/>
<person name="Grafham D.V."/>
<person name="Grant M."/>
<person name="Gribble S."/>
<person name="Griffiths C."/>
<person name="Griffiths M.N.D."/>
<person name="Hall R."/>
<person name="Halls K.S."/>
<person name="Hammond S."/>
<person name="Harley J.L."/>
<person name="Hart E.A."/>
<person name="Heath P.D."/>
<person name="Heathcott R."/>
<person name="Holmes S.J."/>
<person name="Howden P.J."/>
<person name="Howe K.L."/>
<person name="Howell G.R."/>
<person name="Huckle E."/>
<person name="Humphray S.J."/>
<person name="Humphries M.D."/>
<person name="Hunt A.R."/>
<person name="Johnson C.M."/>
<person name="Joy A.A."/>
<person name="Kay M."/>
<person name="Keenan S.J."/>
<person name="Kimberley A.M."/>
<person name="King A."/>
<person name="Laird G.K."/>
<person name="Langford C."/>
<person name="Lawlor S."/>
<person name="Leongamornlert D.A."/>
<person name="Leversha M."/>
<person name="Lloyd C.R."/>
<person name="Lloyd D.M."/>
<person name="Loveland J.E."/>
<person name="Lovell J."/>
<person name="Martin S."/>
<person name="Mashreghi-Mohammadi M."/>
<person name="Maslen G.L."/>
<person name="Matthews L."/>
<person name="McCann O.T."/>
<person name="McLaren S.J."/>
<person name="McLay K."/>
<person name="McMurray A."/>
<person name="Moore M.J.F."/>
<person name="Mullikin J.C."/>
<person name="Niblett D."/>
<person name="Nickerson T."/>
<person name="Novik K.L."/>
<person name="Oliver K."/>
<person name="Overton-Larty E.K."/>
<person name="Parker A."/>
<person name="Patel R."/>
<person name="Pearce A.V."/>
<person name="Peck A.I."/>
<person name="Phillimore B.J.C.T."/>
<person name="Phillips S."/>
<person name="Plumb R.W."/>
<person name="Porter K.M."/>
<person name="Ramsey Y."/>
<person name="Ranby S.A."/>
<person name="Rice C.M."/>
<person name="Ross M.T."/>
<person name="Searle S.M."/>
<person name="Sehra H.K."/>
<person name="Sheridan E."/>
<person name="Skuce C.D."/>
<person name="Smith S."/>
<person name="Smith M."/>
<person name="Spraggon L."/>
<person name="Squares S.L."/>
<person name="Steward C.A."/>
<person name="Sycamore N."/>
<person name="Tamlyn-Hall G."/>
<person name="Tester J."/>
<person name="Theaker A.J."/>
<person name="Thomas D.W."/>
<person name="Thorpe A."/>
<person name="Tracey A."/>
<person name="Tromans A."/>
<person name="Tubby B."/>
<person name="Wall M."/>
<person name="Wallis J.M."/>
<person name="West A.P."/>
<person name="White S.S."/>
<person name="Whitehead S.L."/>
<person name="Whittaker H."/>
<person name="Wild A."/>
<person name="Willey D.J."/>
<person name="Wilmer T.E."/>
<person name="Wood J.M."/>
<person name="Wray P.W."/>
<person name="Wyatt J.C."/>
<person name="Young L."/>
<person name="Younger R.M."/>
<person name="Bentley D.R."/>
<person name="Coulson A."/>
<person name="Durbin R.M."/>
<person name="Hubbard T."/>
<person name="Sulston J.E."/>
<person name="Dunham I."/>
<person name="Rogers J."/>
<person name="Beck S."/>
</authorList>
<dbReference type="PubMed" id="14574404"/>
<dbReference type="DOI" id="10.1038/nature02055"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="5">
<citation type="journal article" date="1993" name="Blood" volume="81" first="2854" last="2859">
<title>Drosophila forkhead homologues are expressed in a lineage-restricted manner in human hematopoietic cells.</title>
<authorList>
<person name="Hromas R."/>
<person name="Moore J."/>
<person name="Johnston T."/>
<person name="Socha C."/>
<person name="Klemsz M."/>
</authorList>
<dbReference type="PubMed" id="8499623"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 68-177</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="6">
<citation type="journal article" date="1994" name="EMBO J." volume="13" first="5002" last="5012">
<title>Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending.</title>
<authorList>
<person name="Pierrou S."/>
<person name="Hellqvist M."/>
<person name="Samuelsson L."/>
<person name="Enerbaeck S."/>
<person name="Carlsson P."/>
</authorList>
<dbReference type="PubMed" id="7957066"/>
<dbReference type="DOI" id="10.1002/j.1460-2075.1994.tb06827.x"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 73-178</scope>
<scope>FUNCTION</scope>
<scope>DNA-BENDING</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2002" name="Genomics" volume="80" first="465" last="472">
<title>Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth.</title>
<authorList>
<person name="Zhou Y."/>
<person name="Kato H."/>
<person name="Asanoma K."/>
<person name="Kondo H."/>
<person name="Arima T."/>
<person name="Kato K."/>
<person name="Matsuda T."/>
<person name="Wake N."/>
</authorList>
<dbReference type="PubMed" id="12408963"/>
<dbReference type="DOI" id="10.1006/geno.2002.6860"/>
</citation>
<scope>FUNCTION</scope>
<scope>INDUCTION</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="10292" last="10297">
<title>FOXC1 transcriptional regulation is mediated by N- and C-terminal activation domains and contains a phosphorylated transcriptional inhibitory domain.</title>
<authorList>
<person name="Berry F.B."/>
<person name="Saleem R.A."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="11782474"/>
<dbReference type="DOI" id="10.1074/jbc.m110266200"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>NUCLEAR LOCALIZATION SIGNAL</scope>
<scope>TRANSCRIPTIONAL ACTIVATION/REPRESSION DOMAINS</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2003" name="Genes Dev." volume="17" first="269" last="281">
<title>Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer.</title>
<authorList>
<person name="Yamagishi H."/>
<person name="Maeda J."/>
<person name="Hu T."/>
<person name="McAnally J."/>
<person name="Conway S.J."/>
<person name="Kume T."/>
<person name="Meyers E.N."/>
<person name="Yamagishi C."/>
<person name="Srivastava D."/>
</authorList>
<dbReference type="PubMed" id="12533514"/>
<dbReference type="DOI" id="10.1101/gad.1048903"/>
</citation>
<scope>FUNCTION</scope>
<scope>DNA-BINDING</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2004" name="Nucleic Acids Res." volume="32" first="4182" last="4193">
<title>Essential structural and functional determinants within the forkhead domain of FOXC1.</title>
<authorList>
<person name="Saleem R.A."/>
<person name="Banerjee-Basu S."/>
<person name="Murphy T.C."/>
<person name="Baxevanis A."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="15299087"/>
<dbReference type="DOI" id="10.1093/nar/gkh742"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>MUTAGENESIS OF PRO-79; LEU-86; ILE-87; ILE-91; ILE-126 AND ARG-127</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2005" name="Mol. Cell. Biol." volume="25" first="1415" last="1424">
<title>FOXC1 transcriptional regulatory activity is impaired by PBX1 in a filamin A-mediated manner.</title>
<authorList>
<person name="Berry F.B."/>
<person name="O'Neill M.A."/>
<person name="Coca-Prados M."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="15684392"/>
<dbReference type="DOI" id="10.1128/mcb.25.4.1415-1424.2005"/>
</citation>
<scope>FUNCTION</scope>
<scope>DNA-BINDING</scope>
<scope>INTERACTION WITH FLNA AND PBX1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="10098" last="10104">
<title>Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade.</title>
<authorList>
<person name="Berry F.B."/>
<person name="Mirzayans F."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="16492674"/>
<dbReference type="DOI" id="10.1074/jbc.m513629200"/>
</citation>
<scope>FUNCTION</scope>
<scope>UBIQUITINATION</scope>
<scope>PHOSPHORYLATION AT SER-272</scope>
<scope>MUTAGENESIS OF THR-68; SER-241; SER-259 AND SER-272</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2008" name="Hum. Mol. Genet." volume="17" first="490" last="505">
<title>FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A.</title>
<authorList>
<person name="Berry F.B."/>
<person name="Skarie J.M."/>
<person name="Mirzayans F."/>
<person name="Fortin Y."/>
<person name="Hudson T.J."/>
<person name="Raymond V."/>
<person name="Link B.A."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="17993506"/>
<dbReference type="DOI" id="10.1093/hmg/ddm326"/>
</citation>
<scope>FUNCTION</scope>
<scope>DNA-BINDING</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2008" name="Invest. Ophthalmol. Vis. Sci." volume="49" first="5243" last="5249">
<title>Human p32 is a novel FOXC1-interacting protein that regulates FOXC1 transcriptional activity in ocular cells.</title>
<authorList>
<person name="Huang L."/>
<person name="Chi J."/>
<person name="Berry F.B."/>
<person name="Footz T.K."/>
<person name="Sharp M.W."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="18676636"/>
<dbReference type="DOI" id="10.1167/iovs.07-1625"/>
</citation>
<scope>INTERACTION WITH C1QBP</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2008" name="Mol. Cell" volume="31" first="438" last="448">
<title>Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.</title>
<authorList>
<person name="Daub H."/>
<person name="Olsen J.V."/>
<person name="Bairlein M."/>
<person name="Gnad F."/>
<person name="Oppermann F.S."/>
<person name="Korner R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Stemmann O."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="18691976"/>
<dbReference type="DOI" id="10.1016/j.molcel.2008.07.007"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-235; SER-241 AND SER-320</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="16">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-235</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="17">
<citation type="journal article" date="2009" name="Anal. Chem." volume="81" first="4493" last="4501">
<title>Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.</title>
<authorList>
<person name="Gauci S."/>
<person name="Helbig A.O."/>
<person name="Slijper M."/>
<person name="Krijgsveld J."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="19413330"/>
<dbReference type="DOI" id="10.1021/ac9004309"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="19">
<citation type="journal article" date="2010" name="Cancer Res." volume="70" first="3870" last="3876">
<title>FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.</title>
<authorList>
<person name="Ray P.S."/>
<person name="Wang J."/>
<person name="Qu Y."/>
<person name="Sim M.S."/>
<person name="Shamonki J."/>
<person name="Bagaria S.P."/>
<person name="Ye X."/>
<person name="Liu B."/>
<person name="Elashoff D."/>
<person name="Hoon D.S."/>
<person name="Walter M.A."/>
<person name="Martens J.W."/>
<person name="Richardson A.L."/>
<person name="Giuliano A.E."/>
<person name="Cui X."/>
</authorList>
<dbReference type="PubMed" id="20406990"/>
<dbReference type="DOI" id="10.1158/0008-5472.can-09-4120"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320 AND SER-521</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="21">
<citation type="journal article" date="2012" name="Int. J. Biol. Sci." volume="8" first="1130" last="1141">
<title>FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition.</title>
<authorList>
<person name="Xu Z.Y."/>
<person name="Ding S.M."/>
<person name="Zhou L."/>
<person name="Xie H.Y."/>
<person name="Chen K.J."/>
<person name="Zhang W."/>
<person name="Xing C.Y."/>
<person name="Guo H.J."/>
<person name="Zheng S.S."/>
</authorList>
<dbReference type="PubMed" id="22991501"/>
<dbReference type="DOI" id="10.7150/ijbs.4769"/>
</citation>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2012" name="J. Biol. Chem." volume="287" first="18318" last="18329">
<title>Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.</title>
<authorList>
<person name="Danciu T.E."/>
<person name="Chupreta S."/>
<person name="Cruz O."/>
<person name="Fox J.E."/>
<person name="Whitman M."/>
<person name="Iniguez-Lluhi J.A."/>
</authorList>
<dbReference type="PubMed" id="22493429"/>
<dbReference type="DOI" id="10.1074/jbc.m112.339424"/>
</citation>
<scope>SUMOYLATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="24">
<citation type="journal article" date="2015" name="Cell Rep." volume="13" first="1046" last="1058">
<title>FOXC1 activates smoothened-independent Hedgehog signaling in basal-like breast cancer.</title>
<authorList>
<person name="Han B."/>
<person name="Qu Y."/>
<person name="Jin Y."/>
<person name="Yu Y."/>
<person name="Deng N."/>
<person name="Wawrowsky K."/>
<person name="Zhang X."/>
<person name="Li N."/>
<person name="Bose S."/>
<person name="Wang Q."/>
<person name="Sakkiah S."/>
<person name="Abrol R."/>
<person name="Jensen T.W."/>
<person name="Berman B.P."/>
<person name="Tanaka H."/>
<person name="Johnson J."/>
<person name="Gao B."/>
<person name="Hao J."/>
<person name="Liu Z."/>
<person name="Buttyan R."/>
<person name="Ray P.S."/>
<person name="Hung M.C."/>
<person name="Giuliano A.E."/>
<person name="Cui X."/>
</authorList>
<dbReference type="PubMed" id="26565916"/>
<dbReference type="DOI" id="10.1016/j.celrep.2015.09.063"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH GLI2</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2016" name="PLoS ONE" volume="11" first="E0167392" last="E0167392">
<title>Forkhead Box C1 regulates human primary keratinocyte terminal differentiation.</title>
<authorList>
<person name="Bin L."/>
<person name="Deng L."/>
<person name="Yang H."/>
<person name="Zhu L."/>
<person name="Wang X."/>
<person name="Edwards M.G."/>
<person name="Richers B."/>
<person name="Leung D.Y."/>
</authorList>
<dbReference type="PubMed" id="27907090"/>
<dbReference type="DOI" id="10.1371/journal.pone.0167392"/>
</citation>
<scope>FUNCTION</scope>
<scope>INDUCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2001" name="Am. J. Hum. Genet." volume="68" first="364" last="372">
<title>A spectrum of FOXC1 mutations suggests gene dosage as a mechanism for developmental defects of the anterior chamber of the eye.</title>
<authorList>
<person name="Nishimura D.Y."/>
<person name="Searby C.C."/>
<person name="Alward W.L."/>
<person name="Walton D."/>
<person name="Craig J.E."/>
<person name="Mackey D.A."/>
<person name="Kawase K."/>
<person name="Kanis A.B."/>
<person name="Patil S.R."/>
<person name="Stone E.M."/>
<person name="Sheffield V.C."/>
</authorList>
<dbReference type="PubMed" id="11170889"/>
<dbReference type="DOI" id="10.1086/318183"/>
</citation>
<scope>VARIANTS RIEG3 LEU-79 AND LEU-131</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2001" name="Am. J. Hum. Genet." volume="68" first="627" last="641">
<title>Analyses of the effects that disease-causing missense mutations have and function of the winged-helix protein FOXC1.</title>
<authorList>
<person name="Saleem R.A."/>
<person name="Banerjee-Basu S."/>
<person name="Berry F.B."/>
<person name="Baxevanis A.D."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="11179011"/>
<dbReference type="DOI" id="10.1086/318792"/>
</citation>
<scope>VARIANTS RIEG3 THR-82; MET-87; SER-112; MET-126 AND LEU-131</scope>
<scope>CHARACTERIZATION OF VARIANTS RIEG3 THR-82; MET-87; SER-112; MET-126 AND LEU-131</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2001" name="Am. J. Ophthalmol." volume="132" first="572" last="575">
<title>A novel (Pro79Thr) mutation in the FKHL7 gene in a Japanese family with Axenfeld-Rieger syndrome.</title>
<authorList>
<person name="Suzuki T."/>
<person name="Takahashi K."/>
<person name="Kuwahara S."/>
<person name="Wada Y."/>
<person name="Abe T."/>
<person name="Tamai M."/>
</authorList>
<dbReference type="PubMed" id="11589884"/>
<dbReference type="DOI" id="10.1016/s0002-9394(01)01059-5"/>
</citation>
<scope>VARIANT RIEG3 THR-79</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2001" name="J. Glaucoma" volume="10" first="477" last="482">
<title>Screening for mutations of Axenfeld-Rieger syndrome caused by FOXC1 gene in Japanese patients.</title>
<authorList>
<person name="Kawase C."/>
<person name="Kawase K."/>
<person name="Taniguchi T."/>
<person name="Sugiyama K."/>
<person name="Yamamoto T."/>
<person name="Kitazawa Y."/>
<person name="Alward W.L."/>
<person name="Stone E.M."/>
<person name="Nishimura D.Y."/>
<person name="Sheffield V.C."/>
</authorList>
<dbReference type="PubMed" id="11740218"/>
<dbReference type="DOI" id="10.1097/00061198-200112000-00007"/>
</citation>
<scope>VARIANTS RIEG3 SER-91 AND HIS-127</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2002" name="Invest. Ophthalmol. Vis. Sci." volume="43" first="3613" last="3616">
<title>Novel mutation in FOXC1 wing region causing Axenfeld-Rieger anomaly.</title>
<authorList>
<person name="Panicker S.G."/>
<person name="Sampath S."/>
<person name="Mandal A.K."/>
<person name="Reddy A.B.M."/>
<person name="Ahmed N."/>
<person name="Hasnain S.E."/>
</authorList>
<dbReference type="PubMed" id="12454026"/>
</citation>
<scope>VARIANT RIEG3 LYS-161</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2003" name="Am. J. Ophthalmol." volume="135" first="368" last="375">
<title>A family with Axenfeld-Rieger syndrome and Peters Anomaly caused by a point mutation (Phe112Ser) in the FOXC1 gene.</title>
<authorList>
<person name="Honkanen R.A."/>
<person name="Nishimura D.Y."/>
<person name="Swiderski R.E."/>
<person name="Bennett S.R."/>
<person name="Hong S."/>
<person name="Kwon Y.H."/>
<person name="Stone E.M."/>
<person name="Sheffield V.C."/>
<person name="Alward W.L.M."/>
</authorList>
<dbReference type="PubMed" id="12614756"/>
<dbReference type="DOI" id="10.1016/s0002-9394(02)02061-5"/>
</citation>
<scope>VARIANT ASGD3 SER-112</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2003" name="Hum. Mol. Genet." volume="12" first="2993" last="3005">
<title>Structural and functional analyses of disease-causing missense mutations in the forkhead domain of FOXC1.</title>
<authorList>
<person name="Saleem R.A."/>
<person name="Banerjee-Basu S."/>
<person name="Berry F.B."/>
<person name="Baxevanis A.D."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="14506133"/>
<dbReference type="DOI" id="10.1093/hmg/ddg324"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS RIEG3 LEU-79; THR-79; THR-82; SER-91; THR-91; SER-112; MET-126; HIS-127 AND LEU-131</scope>
<scope>FUNCTION</scope>
<scope>DNA-BENDING</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2003" name="Invest. Ophthalmol. Vis. Sci." volume="44" first="4608" last="4612">
<title>Identification and analysis of a novel mutation in the FOXC1 forkhead domain.</title>
<authorList>
<person name="Saleem R.A."/>
<person name="Murphy T.C."/>
<person name="Liebmann J.M."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="14578375"/>
<dbReference type="DOI" id="10.1167/iovs.03-0090"/>
</citation>
<scope>VARIANT RIEG3 PHE-86</scope>
<scope>MUTAGENESIS OF LEU-86</scope>
<scope>CHARACTERIZATION OF VARIANT RIEG3 PHE-86</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2004" name="Arch. Ophthalmol." volume="122" first="1527" last="1533">
<title>Axenfeld-Rieger anomaly: a novel mutation in the forkhead box C1 (FOXC1) gene in a 4-generation family.</title>
<authorList>
<person name="Mortemousque B."/>
<person name="Amati-Bonneau P."/>
<person name="Couture F."/>
<person name="Graffan R."/>
<person name="Dubois S."/>
<person name="Colin J."/>
<person name="Bonneau D."/>
<person name="Morissette J."/>
<person name="Lacombe D."/>
<person name="Raymond V."/>
</authorList>
<dbReference type="PubMed" id="15477465"/>
<dbReference type="DOI" id="10.1001/archopht.122.10.1527"/>
</citation>
<scope>VARIANT RIEG3 THR-91</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2004" name="Invest. Ophthalmol. Vis. Sci." volume="45" first="2531" last="2538">
<title>The wing 2 region of the FOXC1 forkhead domain is necessary for normal DNA-binding and transactivation functions.</title>
<authorList>
<person name="Murphy T.C."/>
<person name="Saleem R.A."/>
<person name="Footz T."/>
<person name="Ritch R."/>
<person name="McGillivray B."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="15277473"/>
<dbReference type="DOI" id="10.1167/iovs.04-0167"/>
</citation>
<scope>VARIANTS RIEG3 ARG-165 AND PRO-169</scope>
<scope>CHARACTERIZATION OF VARIANTS RIEG3 LYS-161; ARG-165 AND PRO-169</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="Hum. Mol. Genet." volume="15" first="905" last="919">
<title>Functional interactions between FOXC1 and PITX2 underlie the sensitivity to FOXC1 gene dose in Axenfeld-Rieger syndrome and anterior segment dysgenesis.</title>
<authorList>
<person name="Berry F.B."/>
<person name="Lines M.A."/>
<person name="Oas J.M."/>
<person name="Footz T."/>
<person name="Underhill D.A."/>
<person name="Gage P.J."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="16449236"/>
<dbReference type="DOI" id="10.1093/hmg/ddl008"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS RIEG3 HIS-127 AND LEU-131</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PITX2</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2006" name="Invest. Ophthalmol. Vis. Sci." volume="47" first="3846" last="3852">
<title>Novel mutations of FOXC1 and PITX2 in patients with Axenfeld-Rieger malformations.</title>
<authorList>
<person name="Weisschuh N."/>
<person name="Dressler P."/>
<person name="Schuettauf F."/>
<person name="Wolf C."/>
<person name="Wissinger B."/>
<person name="Gramer E."/>
</authorList>
<dbReference type="PubMed" id="16936096"/>
<dbReference type="DOI" id="10.1167/iovs.06-0343"/>
</citation>
<scope>VARIANTS RIEG3 ARG-79; SER-115; ASP-149 AND VAL-161</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2006" name="Invest. Ophthalmol. Vis. Sci." volume="47" first="5162" last="5162">
<authorList>
<person name="Weisschuh N."/>
<person name="Dressler P."/>
<person name="Schuettauf F."/>
<person name="Wolf C."/>
<person name="Wissinger B."/>
<person name="Gramer E."/>
</authorList>
</citation>
<scope>ERRATUM OF PUBMED:16936096</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2007" name="Arch. Ophthalmol." volume="125" first="128" last="135">
<title>Analyses of a novel L130F missense mutation in FOXC1.</title>
<authorList>
<person name="Ito Y.A."/>
<person name="Footz T.K."/>
<person name="Murphy T.C."/>
<person name="Courtens W."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="17210863"/>
<dbReference type="DOI" id="10.1001/archopht.125.1.128"/>
</citation>
<scope>VARIANT RIEG3 PHE-130</scope>
<scope>CHARACTERIZATION OF VARIANT RIEG3 PHE-130</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2007" name="Mol. Vis." volume="13" first="1005" last="1009">
<title>Novel mutations in the FOXC1 gene in Japanese patients with Axenfeld-Rieger syndrome.</title>
<authorList>
<person name="Fuse N."/>
<person name="Takahashi K."/>
<person name="Yokokura S."/>
<person name="Nishida K."/>
</authorList>
<dbReference type="PubMed" id="17653043"/>
</citation>
<scope>VARIANT RIEG3 PRO-85</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2008" name="Ophthalmic Genet." volume="29" first="67" last="71">
<title>Heterozygous FOXC1 mutation (M161K) associated with congenital glaucoma and aniridia in an infant and a milder phenotype in her mother.</title>
<authorList>
<person name="Khan A.O."/>
<person name="Aldahmesh M.A."/>
<person name="Al-Amri A."/>
</authorList>
<dbReference type="PubMed" id="18484311"/>
<dbReference type="DOI" id="10.1080/13816810801908152"/>
</citation>
<scope>VARIANT ASGD3 LYS-161</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2009" name="Clin. Genet." volume="76" first="296" last="299">
<title>Characterization of a novel FOXC1 mutation, P297S, identified in two individuals with anterior segment dysgenesis.</title>
<authorList>
<person name="Fetterman C.D."/>
<person name="Mirzayans F."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="19793056"/>
<dbReference type="DOI" id="10.1111/j.1399-0004.2009.01210.x"/>
</citation>
<scope>VARIANT ASGD3 SER-297</scope>
<scope>CHARACTERIZATION OF VARIANT ASGD3 SER-297</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2009" name="Invest. Ophthalmol. Vis. Sci." volume="50" first="3573" last="3579">
<title>Severe molecular defects of a novel FOXC1 W152G mutation result in aniridia.</title>
<authorList>
<person name="Ito Y.A."/>
<person name="Footz T.K."/>
<person name="Berry F.B."/>
<person name="Mirzayans F."/>
<person name="Yu M."/>
<person name="Khan A.O."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="19279310"/>
<dbReference type="DOI" id="10.1167/iovs.08-3032"/>
</citation>
<scope>VARIANT ASGD3 GLY-152</scope>
<scope>CHARACTERIZATION OF VARIANT ASGD3 GLY-152</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>CHARACTERIZATION OF VARIANT RIEG3 PHE-130</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2011" name="Invest. Ophthalmol. Vis. Sci." volume="52" first="324" last="333">
<title>Expanding the spectrum of FOXC1 and PITX2 mutations and copy number changes in patients with anterior segment malformations.</title>
<authorList>
<person name="D'haene B."/>
<person name="Meire F."/>
<person name="Claerhout I."/>
<person name="Kroes H.Y."/>
<person name="Plomp A."/>
<person name="Arens Y.H."/>
<person name="de Ravel T."/>
<person name="Casteels I."/>
<person name="De Jaegere S."/>
<person name="Hooghe S."/>
<person name="Wuyts W."/>
<person name="van den Ende J."/>
<person name="Roulez F."/>
<person name="Veenstra-Knol H.E."/>
<person name="Oldenburg R.A."/>
<person name="Giltay J."/>
<person name="Verheij J.B."/>
<person name="de Faber J.T."/>
<person name="Menten B."/>
<person name="De Paepe A."/>
<person name="Kestelyn P."/>
<person name="Leroy B.P."/>
<person name="De Baere E."/>
</authorList>
<dbReference type="PubMed" id="20881294"/>
<dbReference type="DOI" id="10.1167/iovs.10-5309"/>
</citation>
<scope>VARIANTS ASGD3 VAL-109; TRP-131 AND GLU-138</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2013" name="Am. J. Med. Genet. A" volume="161A" first="114" last="119">
<title>Cardiac anomalies in Axenfeld-Rieger syndrome due to a novel FOXC1 mutation.</title>
<authorList>
<person name="Gripp K.W."/>
<person name="Hopkins E."/>
<person name="Jenny K."/>
<person name="Thacker D."/>
<person name="Salvin J."/>
</authorList>
<dbReference type="PubMed" id="23239455"/>
<dbReference type="DOI" id="10.1002/ajmg.a.35697"/>
</citation>
<scope>VARIANT RIEG3 TRP-170</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2015" name="PLoS ONE" volume="10" first="E0119272" last="E0119272">
<title>Hypo- and hypermorphic FOXC1 mutations in dominant glaucoma: transactivation and phenotypic variability.</title>
<authorList>
<person name="Medina-Trillo C."/>
<person name="Sanchez-Sanchez F."/>
<person name="Aroca-Aguilar J.D."/>
<person name="Ferre-Fernandez J.J."/>
<person name="Morales L."/>
<person name="Mendez-Hernandez C.D."/>
<person name="Blanco-Kelly F."/>
<person name="Ayuso C."/>
<person name="Garcia-Feijoo J."/>
<person name="Escribano J."/>
</authorList>
<dbReference type="PubMed" id="25786029"/>
<dbReference type="DOI" id="10.1371/journal.pone.0119272"/>
</citation>
<scope>VARIANT RIEG3 SER-126</scope>
<scope>CHARACTERIZATION OF VARIANT RIEG3 SER-126</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2016" name="Ophthalmic Genet." volume="37" first="111" last="115">
<title>A novel mutation of FOXC1 (R127L) in an Axenfeld-Rieger syndrome family with glaucoma and multiple congenital heart diseases.</title>
<authorList>
<person name="Du R.F."/>
<person name="Huang H."/>
<person name="Fan L.L."/>
<person name="Li X.P."/>
<person name="Xia K."/>
<person name="Xiang R."/>
</authorList>
<dbReference type="PubMed" id="24914578"/>
<dbReference type="DOI" id="10.3109/13816810.2014.924016"/>
</citation>
<scope>VARIANT RIEG3 LEU-127</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2017" name="Hum. Mutat." volume="38" first="169" last="179">
<title>Comparison of bioinformatics prediction, molecular modeling, and functional analyses of FOXC1 mutations in patients with Axenfeld-Rieger syndrome.</title>
<authorList>
<person name="Seifi M."/>
<person name="Footz T."/>
<person name="Taylor S.A."/>
<person name="Walter M.A."/>
</authorList>
<dbReference type="PubMed" id="27804176"/>
<dbReference type="DOI" id="10.1002/humu.23141"/>
</citation>
<scope>VARIANTS RIEG3 ARG-128; TYR-135 AND VAL-161</scope>
<scope>VARIANT ASN-368</scope>
<scope>CHARACTERIZATION OF VARIANTS RIEG3 ARG-128; TYR-135 AND VAL-161</scope>
<scope>CHARACTERIZATION OF VARIANT ASN-368</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<comment type="function">
<text evidence="5 11 12 14 17 18 19 20 22 23 24 26 28 31 32 33 36 39 40 41 42 43">DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes such as eye, bones, cardiovascular, kidney and skin development (PubMed:11782474, PubMed:15299087, PubMed:15684392, PubMed:16492674, PubMed:27907090, PubMed:14506133, PubMed:14578375, PubMed:15277473, PubMed:16449236, PubMed:17210863, PubMed:19793056, PubMed:19279310, PubMed:25786029, PubMed:27804176). Acts either as a transcriptional activator or repressor (PubMed:11782474). Binds to the consensus binding site 5'-[G/C][A/T]AAA[T/C]AA[A/C]-3' in promoter of target genes (PubMed:7957066, PubMed:11782474, PubMed:12533514, PubMed:14506133, PubMed:19793056, PubMed:27804176). Upon DNA-binding, promotes DNA bending (PubMed:7957066, PubMed:14506133). Acts as a transcriptional coactivator (PubMed:26565916). Stimulates Indian hedgehog (Ihh)-induced target gene expression mediated by the transcription factor GLI2, and hence regulates endochondral ossification (By similarity). Acts also as a transcriptional coregulator by increasing DNA-binding capacity of GLI2 in breast cancer cells (PubMed:26565916). Regulates FOXO1 through binding to a conserved element, 5'-GTAAACAAA-3' in its promoter region, implicating FOXC1 as an important regulator of cell viability and resistance to oxidative stress in the eye (PubMed:17993506). Cooperates with transcription factor FOXC2 in regulating expression of genes that maintain podocyte integrity (By similarity). Promotes cell growth inhibition by stopping the cell cycle in the G1 phase through TGFB1-mediated signals (PubMed:12408963). Involved in epithelial-mesenchymal transition (EMT) induction by increasing cell proliferation, migration and invasion (PubMed:20406990, PubMed:22991501). Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression (By similarity). Plays a role in the gene regulatory network essential for epidermal keratinocyte terminal differentiation (PubMed:27907090). Essential developmental transcriptional factor required for mesoderm-derived tissues, such as the somites, skin, bone and cartilage. Positively regulates CXCL12 and stem cell factor expression in bone marrow mesenchymal progenitor cells, and hence plays a role in the development and maintenance of mesenchymal niches for haematopoietic stem and progenitor cells (HSPC). Plays a role in corneal transparency by preventing both blood vessel and lymphatic vessel growth during embryonic development in a VEGF-dependent manner. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression (By similarity). May function as a tumor suppressor (PubMed:12408963).</text>
</comment>
<comment type="subunit">
<text evidence="22 23 30 40">Monomer. Interacts with C1QBP (PubMed:18676636). Interacts (via N-terminus) with GLI2 (via C-terminal internal region); this interaction is direct and increases GLI2 DNA-binding and transcriptional activity through a smoothened (SMO)-independent Hedgehog (Hh) signaling pathway (PubMed:26565916). Interacts (via C-terminus domain) with PITX2 isoform 3 (via homeobox domain) (PubMed:16449236). Interacts with FLNA and PBX1 (PubMed:15684392).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1175253">
<id>Q12948</id>
</interactant>
<interactant intactId="EBI-347528">
<id>Q07021</id>
<label>C1QBP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1175253">
<id>Q12948</id>
</interactant>
<interactant intactId="EBI-350432">
<id>P21333</id>
<label>FLNA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>8</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1175253">
<id>Q12948</id>
</interactant>
<interactant intactId="EBI-301611">
<id>P40424</id>
<label>PBX1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1175253">
<id>Q12948</id>
</interactant>
<interactant intactId="EBI-1175243">
<id>Q99697-3</id>
<label>PITX2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1175253">
<id>Q12948</id>
</interactant>
<interactant intactId="EBI-6248094">
<id>Q9Q2G4</id>
<label>ORF</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="11 18 19 20 22 23 26 31 32 33 39 40 41">Nucleus</location>
</subcellularLocation>
<text evidence="5 22 23">Colocalizes with PITX2 isoform 3 in the nucleus at subnuclear chromatine regions (PubMed:16449236). Colocalizes with CBX5 to a heterochromatin-rich region of the nucleus (PubMed:15684392). Colocalizes with GLI2 in the nucleus (By similarity).</text>
</comment>
<comment type="tissue specificity">
<text evidence="33 36 40 42 44">Expressed in keratinocytes of epidermis and hair follicle (PubMed:27907090). Expressed strongly in microvascular invasion (MVI) formation, basal-like breast cancer (BLBC) and hepatocellular tumors (PubMed:20406990, PubMed:22991501). Expressed in breast cancers (at protein level) (PubMed:26565916). Expressed in hematopoietic cells (PubMed:8499623).</text>
</comment>
<comment type="induction">
<text evidence="12 42">Up-regulated during the progression of epidermal keratinocyte differentiation (at protein level) (PubMed:27907090). Up-regulated upon calcium-mediated keratinocyte differentiation (PubMed:27907090). Up-regulated by transforming growth factor TGFB1 (PubMed:12408963).</text>
</comment>
<comment type="PTM">
<text evidence="11 24 31 39">Phosphorylated (PubMed:11782474, PubMed:19279310, PubMed:25786029). Phosphorylated on Ser-272 in response to epidermal growth factor (EGF) in a ERK1/2 MAPK-dependent signaling pathway; phosphorylation contributes to its protein stability and transcriptional activity (PubMed:16492674).</text>
</comment>
<comment type="PTM">
<text evidence="35">Sumoylated preferentially with SUMO2 or SUMO3 (PubMed:22493429). Desumoylated by SENP2 (PubMed:22493429).</text>
</comment>
<comment type="PTM">
<text evidence="24">Ubiquitinated, leading to its proteasomal degradation (PubMed:16492674).</text>
</comment>
<comment type="disease" evidence="7 8 9 10 13 15 17 18 19 21 23 25 26 27 31 37 38 39 41 46">
<disease id="DI-01266">
<name>Axenfeld-Rieger syndrome 3</name>
<acronym>RIEG3</acronym>
<description>An autosomal dominant disorder of morphogenesis that results in abnormal development of the anterior segment of the eye, and results in blindness from glaucoma in approximately 50% of affected individuals. Features include posterior corneal embryotoxon, prominent Schwalbe line and iris adhesion to the Schwalbe line, hypertelorism, hypodontia, sensorineural deafness, redundant periumbilical skin, and cardiovascular defects such as patent ductus arteriosus and atrial septal defect. When associated with tooth anomalies, the disorder is known as Rieger syndrome.</description>
<dbReference type="MIM" id="602482"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="16 29 31 32 34 45">
<disease id="DI-01832">
<name>Anterior segment dysgenesis 3</name>
<acronym>ASGD3</acronym>
<description>A form of anterior segment dysgenesis, a group of defects affecting anterior structures of the eye including cornea, iris, lens, trabecular meshwork, and Schlemm canal. Anterior segment dysgeneses result from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to components of the anterior chamber during eye development. Different anterior segment anomalies may exist alone or in combination, including iris hypoplasia, enlarged or reduced corneal diameter, corneal vascularization and opacity, posterior embryotoxon, corectopia, polycoria, abnormal iridocorneal angle, ectopia lentis, and anterior synechiae between the iris and posterior corneal surface. Clinical conditions falling within the phenotypic spectrum of anterior segment dysgeneses include aniridia, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis. ASGD3 inheritance is autosomal dominant.</description>
<dbReference type="MIM" id="601631"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/FOXC1ID40624ch6p25.html"/>
</comment>
<dbReference type="EMBL" id="AF048693">
<property type="protein sequence ID" value="AAC18081.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF078096">
<property type="protein sequence ID" value="AAC72915.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AY228704">
<property type="protein sequence ID" value="AAP15181.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AL034344">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="L12143">
<property type="protein sequence ID" value="AAK13575.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U13221">
<property type="protein sequence ID" value="AAA92038.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS4473.1"/>
<dbReference type="PIR" id="S51626">
<property type="entry name" value="S51626"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001444.2">
<property type="nucleotide sequence ID" value="NM_001453.2"/>
</dbReference>
<dbReference type="SMR" id="Q12948"/>
<dbReference type="BioGRID" id="108585">
<property type="interactions" value="57"/>
</dbReference>
<dbReference type="IntAct" id="Q12948">
<property type="interactions" value="46"/>
</dbReference>
<dbReference type="MINT" id="Q12948"/>
<dbReference type="STRING" id="9606.ENSP00000370256"/>
<dbReference type="iPTMnet" id="Q12948"/>
<dbReference type="PhosphoSitePlus" id="Q12948"/>
<dbReference type="BioMuta" id="FOXC1"/>
<dbReference type="DMDM" id="13638267"/>
<dbReference type="EPD" id="Q12948"/>
<dbReference type="jPOST" id="Q12948"/>
<dbReference type="MassIVE" id="Q12948"/>
<dbReference type="PaxDb" id="Q12948"/>
<dbReference type="PeptideAtlas" id="Q12948"/>
<dbReference type="PRIDE" id="Q12948"/>
<dbReference type="ProteomicsDB" id="59043"/>
<dbReference type="Antibodypedia" id="9213">
<property type="antibodies" value="409 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000645831">
<property type="protein sequence ID" value="ENSP00000493906"/>
<property type="gene ID" value="ENSG00000054598"/>
</dbReference>
<dbReference type="GeneID" id="2296"/>
<dbReference type="KEGG" id="hsa:2296"/>
<dbReference type="CTD" id="2296"/>
<dbReference type="DisGeNET" id="2296"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000054598.6"/>
<dbReference type="GeneCards" id="FOXC1"/>
<dbReference type="HGNC" id="HGNC:3800">
<property type="gene designation" value="FOXC1"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000054598">
<property type="expression patterns" value="Group enriched (retina, salivary gland)"/>
</dbReference>
<dbReference type="MalaCards" id="FOXC1"/>
<dbReference type="MIM" id="601090">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="601631">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="602482">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_Q12948"/>
<dbReference type="OpenTargets" id="ENSG00000054598"/>
<dbReference type="Orphanet" id="98978">
<property type="disease" value="Axenfeld anomaly"/>
</dbReference>
<dbReference type="Orphanet" id="782">
<property type="disease" value="Axenfeld-Rieger syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="250923">
<property type="disease" value="Isolated aniridia"/>
</dbReference>
<dbReference type="Orphanet" id="708">
<property type="disease" value="Peters anomaly"/>
</dbReference>
<dbReference type="Orphanet" id="91483">
<property type="disease" value="Rieger anomaly"/>
</dbReference>
<dbReference type="PharmGKB" id="PA28217"/>
<dbReference type="eggNOG" id="KOG2294">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00940000162303"/>
<dbReference type="HOGENOM" id="CLU_035722_3_0_1"/>
<dbReference type="InParanoid" id="Q12948"/>
<dbReference type="KO" id="K09396"/>
<dbReference type="OMA" id="GRLTSWY"/>
<dbReference type="OrthoDB" id="1270467at2759"/>
<dbReference type="PhylomeDB" id="Q12948"/>
<dbReference type="TreeFam" id="TF316127"/>
<dbReference type="PathwayCommons" id="Q12948"/>
<dbReference type="SignaLink" id="Q12948"/>
<dbReference type="SIGNOR" id="Q12948"/>
<dbReference type="BioGRID-ORCS" id="2296">
<property type="hits" value="15 hits in 893 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="FOXC1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="GeneWiki" id="Forkhead_box_C1"/>
<dbReference type="GenomeRNAi" id="2296"/>
<dbReference type="Pharos" id="Q12948">
<property type="development level" value="Tbio"/>
</dbReference>
<dbReference type="PRO" id="PR:Q12948"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 6"/>
</dbReference>
<dbReference type="RNAct" id="Q12948">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000054598">
<property type="expression patterns" value="Expressed in parotid gland and 233 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="Q12948">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="Q12948">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0000790">
<property type="term" value="C:nuclear chromatin"/>
<property type="evidence" value="ECO:0000247"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:0005720">
<property type="term" value="C:nuclear heterochromatin"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003677">
<property type="term" value="F:DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008301">
<property type="term" value="F:DNA binding, bending"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001228">
<property type="term" value="F:DNA-binding transcription activator activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:0003700">
<property type="term" value="F:DNA-binding transcription factor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000981">
<property type="term" value="F:DNA-binding transcription factor activity, RNA polymerase II-specific"/>
<property type="evidence" value="ECO:0000247"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:1990841">
<property type="term" value="F:promoter-specific chromatin binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000978">
<property type="term" value="F:RNA polymerase II cis-regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000977">
<property type="term" value="F:RNA polymerase II transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="NTNU_SB"/>
</dbReference>
<dbReference type="GO" id="GO:0043565">
<property type="term" value="F:sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008134">
<property type="term" value="F:transcription factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000976">
<property type="term" value="F:transcription regulatory region sequence-specific DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0009653">
<property type="term" value="P:anatomical structure morphogenesis"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0001525">
<property type="term" value="P:angiogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0048844">
<property type="term" value="P:artery morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001974">
<property type="term" value="P:blood vessel remodeling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043010">
<property type="term" value="P:camera-type eye development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0060038">
<property type="term" value="P:cardiac muscle cell proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030154">
<property type="term" value="P:cell differentiation"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0016477">
<property type="term" value="P:cell migration"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008283">
<property type="term" value="P:cell population proliferation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1990869">
<property type="term" value="P:cellular response to chemokine"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071364">
<property type="term" value="P:cellular response to epidermal growth factor stimulus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0021549">
<property type="term" value="P:cerebellum development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070098">
<property type="term" value="P:chemokine-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030199">
<property type="term" value="P:collagen fibril organization"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0035050">
<property type="term" value="P:embryonic heart tube development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001958">
<property type="term" value="P:endochondral ossification"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001654">
<property type="term" value="P:eye development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0008354">
<property type="term" value="P:germ cell migration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0072010">
<property type="term" value="P:glomerular epithelium development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030203">
<property type="term" value="P:glycosaminoglycan metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007507">
<property type="term" value="P:heart development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0001701">
<property type="term" value="P:in utero embryonic development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001822">
<property type="term" value="P:kidney development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032808">
<property type="term" value="P:lacrimal gland development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001945">
<property type="term" value="P:lymph vessel development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0036438">
<property type="term" value="P:maintenance of lens transparency"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014031">
<property type="term" value="P:mesenchymal cell development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016525">
<property type="term" value="P:negative regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902257">
<property type="term" value="P:negative regulation of apoptotic process involved in outflow tract morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1901491">
<property type="term" value="P:negative regulation of lymphangiogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045930">
<property type="term" value="P:negative regulation of mitotic cell cycle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000122">
<property type="term" value="P:negative regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014032">
<property type="term" value="P:neural crest cell development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007219">
<property type="term" value="P:Notch signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042475">
<property type="term" value="P:odontogenesis of dentin-containing tooth"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001541">
<property type="term" value="P:ovarian follicle development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048341">
<property type="term" value="P:paraxial mesoderm formation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1904798">
<property type="term" value="P:positive regulation of core promoter binding"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043388">
<property type="term" value="P:positive regulation of DNA binding"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010718">
<property type="term" value="P:positive regulation of epithelial to mesenchymal transition"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1901534">
<property type="term" value="P:positive regulation of hematopoietic progenitor cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902038">
<property type="term" value="P:positive regulation of hematopoietic stem cell differentiation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045618">
<property type="term" value="P:positive regulation of keratinocyte differentiation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045944">
<property type="term" value="P:positive regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097746">
<property type="term" value="P:regulation of blood vessel diameter"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0046620">
<property type="term" value="P:regulation of organ growth"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006357">
<property type="term" value="P:regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0006355">
<property type="term" value="P:regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001756">
<property type="term" value="P:somitogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001657">
<property type="term" value="P:ureteric bud development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048010">
<property type="term" value="P:vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0038084">
<property type="term" value="P:vascular endothelial growth factor signaling pathway"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0055010">
<property type="term" value="P:ventricular cardiac muscle tissue morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="CDD" id="cd00059">
<property type="entry name" value="FH"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="1.10.10.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR001766">
<property type="entry name" value="Fork_head_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR018122">
<property type="entry name" value="TF_fork_head_CS_1"/>
</dbReference>
<dbReference type="InterPro" id="IPR030456">
<property type="entry name" value="TF_fork_head_CS_2"/>
</dbReference>
<dbReference type="InterPro" id="IPR036388">
<property type="entry name" value="WH-like_DNA-bd_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR036390">
<property type="entry name" value="WH_DNA-bd_sf"/>
</dbReference>
<dbReference type="Pfam" id="PF00250">
<property type="entry name" value="Forkhead"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00053">
<property type="entry name" value="FORKHEAD"/>
</dbReference>
<dbReference type="SMART" id="SM00339">
<property type="entry name" value="FH"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF46785">
<property type="entry name" value="SSF46785"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00657">
<property type="entry name" value="FORK_HEAD_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00658">
<property type="entry name" value="FORK_HEAD_2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50039">
<property type="entry name" value="FORK_HEAD_3"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0037">Angiogenesis</keyword>
<keyword id="KW-0209">Deafness</keyword>
<keyword id="KW-0217">Developmental protein</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0238">DNA-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-1059">Peters anomaly</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0678">Repressor</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="chain" description="Forkhead box protein C1" id="PRO_0000091806">
<location>
<begin position="1"/>
<end position="553"/>
</location>
</feature>
<feature type="DNA-binding region" description="Fork-head" evidence="6">
<location>
<begin position="77"/>
<end position="168"/>
</location>
</feature>
<feature type="region of interest" description="Required for transcriptional activation" evidence="11">
<location>
<begin position="1"/>
<end position="51"/>
</location>
</feature>
<feature type="region of interest" description="Required for transcriptional inhibition" evidence="11">
<location>
<begin position="215"/>
<end position="366"/>
</location>
</feature>
<feature type="region of interest" description="Required for transcriptional activation" evidence="11">
<location>
<begin position="466"/>
<end position="553"/>
</location>
</feature>
<feature type="short sequence motif" description="Nuclear localization signal 1 (NLS 1)" evidence="11">
<location>
<begin position="78"/>
<end position="93"/>
</location>
</feature>
<feature type="short sequence motif" description="Nuclear localization signal 2 (NLS 2)" evidence="11">
<location>
<begin position="168"/>
<end position="176"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Ala">
<location>
<begin position="28"/>
<end position="33"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Arg">
<location>
<begin position="169"/>
<end position="173"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Pro">
<location>
<begin position="194"/>
<end position="197"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Ser">
<location>
<begin position="262"/>
<end position="272"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Pro">
<location>
<begin position="292"/>
<end position="297"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Gly">
<location>
<begin position="375"/>
<end position="382"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Ser">
<location>
<begin position="438"/>
<end position="445"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Gly">
<location>
<begin position="447"/>
<end position="456"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Ala">
<location>
<begin position="486"/>
<end position="495"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="1 2">
<location>
<position position="235"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="2">
<location>
<position position="241"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="24">
<location>
<position position="272"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="2 3 4">
<location>
<position position="320"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="3">
<location>
<position position="521"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; no change on DNA bending activity." id="VAR_058722" evidence="7 17">
<original>P</original>
<variation>L</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3." id="VAR_058723" evidence="25">
<original>P</original>
<variation>R</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; no change on DNA bending activity." id="VAR_058724" evidence="9 17">
<original>P</original>
<variation>T</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs104893953." id="VAR_007944" evidence="8 17 46">
<original>S</original>
<variation>T</variation>
<location>
<position position="82"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; unknown pathological significance." id="VAR_078501" evidence="27">
<original>A</original>
<variation>P</variation>
<location>
<position position="85"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no change in location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs886039568." id="VAR_058725" evidence="18">
<original>L</original>
<variation>F</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; loss of protein stability; dbSNP:rs104893954." id="VAR_007945" evidence="8 46">
<original>I</original>
<variation>M</variation>
<location>
<position position="87"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; no change on DNA bending activity." id="VAR_058726" evidence="10 17">
<original>I</original>
<variation>S</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; no change on DNA bending activity." id="VAR_058727" evidence="17 21">
<original>I</original>
<variation>T</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3; dbSNP:rs917382067." id="VAR_078502" evidence="34">
<original>M</original>
<variation>V</variation>
<location>
<position position="109"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3 and RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs104893951." id="VAR_007815" evidence="8 16 17 45">
<original>F</original>
<variation>S</variation>
<location>
<position position="112"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3." id="VAR_058728" evidence="25">
<original>Y</original>
<variation>S</variation>
<location>
<position position="115"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3 and RIEG3; with glaucoma; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs104893958." id="VAR_007816" evidence="8 17 45">
<original>I</original>
<variation>M</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; hypomorphic mutation; decreased protein abundance; decreased protein stability; changed post-translational phosphorylation; decreased location at the nucleus; novel location at the cytoplasm; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs483352810." id="VAR_078503" evidence="39">
<original>I</original>
<variation>S</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs1085307884." id="VAR_058729" evidence="10 17 23">
<original>R</original>
<variation>H</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; dbSNP:rs1085307884." id="VAR_078504" evidence="38">
<original>R</original>
<variation>L</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no effect on protein abundance; increased protein stability; decreased location at nucleus; loss of transcription regulatory region DNA binding; loss of sequence-specific DNA binding transcription factor activity." id="VAR_078505" evidence="41">
<original>H</original>
<variation>R</variation>
<location>
<position position="128"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no effect on protein abundance; changed post-translational phosphorylation; novel location at aggresome, aggregation correspond to microtubule-dependent inclusion bodies; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs121909338." id="VAR_058730" evidence="26 31">
<original>L</original>
<variation>F</variation>
<location>
<position position="130"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3 and ASGD3; with glaucoma; decreased location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs104893957." id="VAR_007817" evidence="7 8 17 23 45">
<original>S</original>
<variation>L</variation>
<location>
<position position="131"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3." id="VAR_078506" evidence="34">
<original>S</original>
<variation>W</variation>
<location>
<position position="131"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; decreased protein abundance; decreased protein stability; decreased location at nucleus; loss of transcription regulatory region DNA binding; loss of sequence-specific DNA binding transcription factor activity." id="VAR_078507" evidence="41">
<original>C</original>
<variation>Y</variation>
<location>
<position position="135"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3." id="VAR_078508" evidence="34">
<original>K</original>
<variation>E</variation>
<location>
<position position="138"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3." id="VAR_058731" evidence="25">
<original>G</original>
<variation>D</variation>
<location>
<position position="149"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3; no change in protein abundance; changed post-translational phosphorylation; changed protein structure; decreased location at the nucleus; novel location at the cytoplasm; increased protein aggregation, aggregation do not correspond to microtubule-dependent inclusion bodies; loss of transcription regulatory region DNA binding; loss of sequence-specific DNA binding transcription factor activity." id="VAR_078509" evidence="31">
<original>W</original>
<variation>G</variation>
<location>
<position position="152"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3 and ASGD3; no change in location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity." id="VAR_018150" evidence="13 15 19 29">
<original>M</original>
<variation>K</variation>
<location>
<position position="161"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no effect on protein abundance; no effect on protein stability; no effect on location at nucleus; no effect on transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity." id="VAR_058732" evidence="25 41">
<original>M</original>
<variation>V</variation>
<location>
<position position="161"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no change in location at the nucleus; no effect on transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity." id="VAR_058733" evidence="19">
<original>G</original>
<variation>R</variation>
<location>
<position position="165"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; no change in location at the nucleus; decreased transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity." id="VAR_058734" evidence="19">
<original>R</original>
<variation>P</variation>
<location>
<position position="169"/>
</location>
</feature>
<feature type="sequence variant" description="In RIEG3; unknown pathological significance." id="VAR_078510" evidence="37">
<original>R</original>
<variation>W</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence variant" description="In ASGD3; no effect on protein abundance; increased protein stability; no effect on nuclear location; no effect on transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP:rs79691946." id="VAR_078511" evidence="32">
<original>P</original>
<variation>S</variation>
<location>
<position position="297"/>
</location>
</feature>
<feature type="sequence variant" description="No effect on protein abundance; no effect on protein stability; no effect on nuclear location; no effect on transcription regulatory region DNA binding; no effect on sequence-specific DNA binding transcription factor activity." id="VAR_078512" evidence="41">
<original>T</original>
<variation>N</variation>
<location>
<position position="368"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on protein stability. No effect on transcriptional activity." evidence="24">
<original>T</original>
<variation>A</variation>
<location>
<position position="68"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>P</original>
<variation>A</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>P</original>
<variation>E</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>P</original>
<variation>K</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>L</original>
<variation>A</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>L</original>
<variation>E</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>L</original>
<variation>K</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="mutagenesis site" description="Severely disrupts the protein function." evidence="18">
<original>L</original>
<variation>P</variation>
<location>
<position position="86"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of protein stability." evidence="20">
<original>I</original>
<variation>A</variation>
<variation>E</variation>
<variation>K</variation>
<location>
<position position="87"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>A</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>E</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. No effect on DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>K</variation>
<location>
<position position="91"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>A</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>E</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>I</original>
<variation>K</variation>
<location>
<position position="126"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>R</original>
<variation>A</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>R</original>
<variation>E</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased nuclear localization. Decreased DNA-binding activity. Decreased transcriptional activity." evidence="20">
<original>R</original>
<variation>K</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protein stability. No effect on transcriptional activity." evidence="24">
<original>S</original>
<variation>A</variation>
<location>
<position position="241"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on protein stability. No effect on transcriptional activity." evidence="24">
<original>S</original>
<variation>A</variation>
<location>
<position position="259"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased protein stability. Decreased transcriptional activity." evidence="24">
<original>S</original>
<variation>A</variation>
<location>
<position position="272"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; AAK13575." ref="5" evidence="47">
<original>QPQPKDMV</original>
<variation>RSRSPRHG</variation>
<location>
<begin position="70"/>
<end position="77"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; AAK13575." ref="5" evidence="47">
<original>L</original>
<variation>Q</variation>
<location>
<position position="101"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 2; AAC72915." ref="2" evidence="47">
<original>V</original>
<variation>L</variation>
<location>
<position position="180"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 2; AAC72915." ref="2" evidence="47">
<original>RQPP</original>
<variation>ASPR</variation>
<location>
<begin position="199"/>
<end position="202"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAC18081 and 3; AAP15181." ref="1 3" evidence="47">
<original>D</original>
<variation>N</variation>
<location>
<position position="426"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18691976"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q61572"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00089"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11170889"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11179011"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11589884"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11740218"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11782474"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12408963"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12454026"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12533514"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12592227"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12614756"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14506133"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14578375"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15277473"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15299087"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15477465"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15684392"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16449236"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16492674"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16936096"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17210863"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17653043"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17993506"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18484311"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18676636"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19279310"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19793056"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20406990"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20881294"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22493429"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22991501"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23239455"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24914578"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25786029"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26565916"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27804176"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27907090"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7957066"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8499623"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9620769"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9792859"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000305"/>
<sequence length="553" mass="56789" checksum="59C6FB94303ED59A" modified="2001-04-27" version="3">MQARYSVSSPNSLGVVPYLGGEQSYYRAAAAAAGGGYTAMPAPMSVYSHPAHAEQYPGGMARAYGPYTPQPQPKDMVKPPYSYIALITMAIQNAPDKKITLNGIYQFIMDRFPFYRDNKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDAVKDKEEKDRLHLKEPPPPGRQPPPAPPEQADGNAPGPQPPPVRIQDIKTENGTCPSPPQPLSPAAALGSGSAAAVPKIESPDSSSSSLSSGSSPPGSLPSARPLSLDGADSAPPPPAPSAPPPHHSQGFSVDNIMTSLRGSPQSAAAELSSGLLASAAASSRAGIAPPLALGAYSPGQSSLYSSPCSQTSSAGSSGGGGGGAGAAGGAGGAGTYHCNLQAMSLYAAGERGGHLQGAPGGAGGSAVDDPLPDYSLPPVTSSSSSSLSHGGGGGGGGGGQEAGHHPAAHQGRLTSWYLNQAGGDLGHLASAAAAAAAAGYPGQQQNFHSVREMFESQRIGLNNSPVNGNSSCQMAFPSSQSLYRTSGAFVYDCSKF</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

